PHENTrials Blog
The FDA approves a new prostate cancer combination treatment based upon a successful clinical trial
The U.S. Food and Drug Administration (FDA) recently approved TALZENNA (talazoparib) in combination with XTANDI (enzalutamide) for the treatment of adult patients with homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer...
PHEN’s Educational Resources Highlighted During Recent May Meeting
Newly diagnosed prostate cancer patients often don’t know where to start. That’s why PHEN’s Prostate Cancer Disparity Rally held in April emphasized patient educational resources to help men learn about early detection as well as better understand their treatment...
This information is for educational purposes only and not intended as medical advice.
Patients should consult their medical doctor for advice and recommendations about specific clinical trials.